Bolt Biotherapeutics (NASDAQ:BOLT) Announces Quarterly Earnings Results

Bolt Biotherapeutics (NASDAQ:BOLT) issued its earnings results on Tuesday. The company reported ($4.31) EPS for the quarter, missing the consensus estimate of ($2.85) by ($1.46), FiscalAI reports. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $1.50 million. Bolt Biotherapeutics had a negative return on equity of 92.54% and a negative net margin of 433.74%.

Bolt Biotherapeutics Trading Up 1.7%

Shares of NASDAQ:BOLT traded up $0.08 during midday trading on Tuesday, hitting $4.78. 21,057 shares of the stock were exchanged, compared to its average volume of 25,356. The stock has a market capitalization of $9.18 million, a price-to-earnings ratio of -0.27 and a beta of 1.10. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.59 and a current ratio of 3.59. The business’s 50-day moving average price is $4.58 and its 200 day moving average price is $5.14. Bolt Biotherapeutics has a 12 month low of $3.91 and a 12 month high of $9.25.

Wall Street Analysts Forecast Growth

Several brokerages have commented on BOLT. Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Monday, April 20th. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Bolt Biotherapeutics in a research note on Friday, March 13th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $34.00.

Institutional Trading of Bolt Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in BOLT. Squarepoint Ops LLC grew its holdings in shares of Bolt Biotherapeutics by 19.8% during the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after purchasing an additional 2,448 shares during the last quarter. Shay Capital LLC bought a new stake in shares of Bolt Biotherapeutics during the third quarter worth about $85,000. Susquehanna International Group LLP bought a new stake in shares of Bolt Biotherapeutics during the third quarter worth about $89,000. Finally, Renaissance Technologies LLC boosted its holdings in Bolt Biotherapeutics by 92.2% in the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock valued at $301,000 after acquiring an additional 26,400 shares during the last quarter. 86.70% of the stock is currently owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.